Editas Medicine Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Editas Medicine Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- EDIT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001650664
- EIN
- 46-4097528
Board of directors
-
Akshay Vaishnaw · DirectorSince 2023
-
Andrew Hirsch · DirectorSince 2023
-
Bernadette Connaughton · DirectorSince 2023
-
David Scadden · DirectorSince 2023
-
Elliott M. Levy · DirectorSince 2023
-
Emma Reeve · DirectorSince 2023
-
Gilmore Neil O'Neill · Director · CEOSince 2023
-
Jessica Hopfield · DirectorSince 2023
-
Meeta Chatterjee · DirectorSince 2023
-
Patrick Thomas Ellinor II · DirectorSince 2026
Chief executives
Gilmore Neil O'Neill
· CEO
Dates unknown
Board connections
8 of this board's directors also sit on 11 other boards.
- via David Scadden
- via Andrew Hirsch
- via Bernadette Connaughton
- via Akshay Vaishnaw
- via Jessica Hopfield
- via Jessica Hopfield
- via Elliott M. Levy
- via Emma Reeve
- via Akshay Vaishnaw
- via Meeta Chatterjee
- via Emma Reeve
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $106,688
- 14 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 3, 2026 | Burkly Linda Officer (EVP, CHIEF SCIENTIFIC OFFICER) | Open-market sale | −709 | $3.04 | $2,153 |
| Sep 3, 2026 | Gilmore Neil O'Neill Director, Officer (CEO) | Open-market sale | −5,124 | $3.04 | $15,563 |
| Sep 3, 2026 | Parison Amy Officer (SVP, Chief Financial Officer) | Open-market sale | −453 | $3.04 | $1,376 |
| Aug 3, 2026 | Parison Amy Officer (SVP, Chief Financial Officer) | Open-market sale | −678 | $2.58 | $1,749 |
| Jul 28, 2026 | Burkly Linda Officer (EVP, CHIEF SCIENTIFIC OFFICER) | Open-market sale | −4,928 | $2.67 | $13,158 |
| Jun 3, 2026 | Parison Amy Officer (SVP, Chief Financial Officer) | Open-market sale | −464 | $2.70 | $1,253 |
| Jun 3, 2026 | Gilmore Neil O'Neill Director, Officer (CEO) | Open-market sale | −15,380 | $2.70 | $41,526 |
| Jun 3, 2026 | Burkly Linda Officer (EVP, CHIEF SCIENTIFIC OFFICER) | Open-market sale | −731 | $2.70 | $1,974 |
| Mar 3, 2026 | Gilmore Neil O'Neill Director, Officer (CEO) | Open-market sale | −5,394 | $2.02 | $10,896 |
| Mar 3, 2026 | Parison Amy Officer (SVP, Chief Financial Officer) | Open-market sale | −474 | $2.02 | $957 |
| Mar 3, 2026 | Burkly Linda Officer (EVP, CHIEF SCIENTIFIC OFFICER) | Open-market sale | −749 | $2.02 | $1,513 |
| Dec 3, 2025 | Burkly Linda Officer (EVP, CHIEF SCIENTIFIC OFFICER) | Open-market sale | −713 | $2.15 | $1,533 |
| Dec 3, 2025 | Gilmore Neil O'Neill Director, Officer (CEO) | Open-market sale | −5,603 | $2.15 | $12,046 |
| Dec 3, 2025 | Parison Amy Officer (SVP, Chief Financial Officer) | Open-market sale | −461 | $2.15 | $991 |
| Sep 3, 2025 | Burkly Linda Officer (EVP, CHIEF SCIENTIFIC OFFICER) | Open-market sale | −710 | $2.60 | $1,846 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.